Stock SCPH SCPHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights scPharmaceuticals Inc.

Equities

SCPH

US8106481059

Real-time Estimate Cboe BZX
Other stock markets
 07:44:00 10/05/2024 pm IST 		5-day change 1st Jan Change
4.69 USD -2.49% Intraday chart for scPharmaceuticals Inc. +2.25% -24.00%
24/04 ScPharmaceuticals Inc. Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of Furoscix Auto-Injector (Furosemide 80Mg/Ml) Injection CI
13/03 Transcript : ScPharmaceuticals Inc., Q4 2023 Earnings Call, Mar 13, 2024

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ScPharmaceuticals Inc. Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of Furoscix Auto-Injector (Furosemide 80Mg/Ml) Injection
CI
ScPharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
ScPharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
ScPharmaceuticals Expects Higher Q4 Product Sales
MT
ScPharmaceuticals Inc. Provides Revenue Guidance for the Full Year 2023
CI
ScPharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Scpharmaceuticals Announces Positive Feedback from Two Fda Meetings on Key Long-Term Growth Initiatives
CI
ScPharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
ScPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion
CI
ScPharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
SCPHARMACEUTICALS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
ScPharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
CI
ScPharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
CI
ScPharmaceuticals Inc. Announces Launch and Commercial Availability of FUROSCIX® (Furosemide Injection)
CI
ScPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update
CI
ScPharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
ScPharmaceuticals Inc. Revises Earnings Guidance for the Year 2022
CI
Top Midday Decliners
MT
U.S. FDA approves ScPharmaceuticals' heart failure therapy
RE
U.S. FDA approves ScPharmaceuticals' heart failure therapy
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SCPH Stock
  4. News scPharmaceuticals Inc.
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW